Results 161 to 170 of about 748,749 (317)

Placebos, Active Placebos, and Clinical Trials [PDF]

Clinical Therapeutics, 2017
openaire   +2 more sources

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial. [PDF]

Cancer
Mikkelsen SU, Al-Mousawi A, Puglisi AB, Vallentin AP, Mortensen AØ, Madaj Z, Hinoue T, Ottesen HN, Jespersen JS, Gillberg L, Tulstrup M, Hansen NR, Hansen JW, Andersen MK, Thomas SL, Isaguirre C, Sheldon R, Adams M, Burgos R, Baylin S, Mortensen BK, Lee O'Connell C, Tang Severinsen M, Laird PW, Lykkesfeldt J, Jones P, Grønbæk K.   +26 more
europepmc   +1 more source

To Ask or Not to Ask: Does Inquiring About Participants' Expectations Influence the Placebo Effect? A Placebo Mechanism Study in Healthy Volunteers. [PDF]

Eur J Pain
Lunde SJ, Emborg C, Kothari SF, Foldager L, Geers AL, Vase L.   +5 more
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

The Prefrontal Cortex and Suggestion: Hypnosis vs. Placebo effects

Frontiers in Psychology, 2016
Benjamin Andrew Parris
doaj   +1 more source

Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials. [PDF]

Diabetes Metab Syndr Obes
Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, Zeng Y, Wu Y, Bai H, Zhang Q, Xiao X.   +10 more
europepmc   +1 more source

Manipulating reading skills using the placebo effect: description of the research project.

openL’obiettivo di questo elaborato è quello di descrivere un progetto di ricerca, finalizzato a indagare la presenza di effetti placebo e nocebo sulle abilità di lettura di studenti universitari.
DEMONTE, ELENA
core  

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Efficacy of donepezil in patients with chronic tinnitus. [PDF]

Clinics (Sao Paulo)
Watanabe EM, Vasconcelos LGE, Bonadia-Moraes MF, Husain FT, Duarte NJC, Oiticica J.   +5 more
europepmc   +1 more source